Xuanzhu Biopharmaceutical Co Ltd

02575

Company Profile

  • Business description

    Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China's pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology, and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology, and high-growth potential therapeutic areas such as NASH.

  • Contact

    Zhubang 2000 Business Center
    2107, Building 2
    Balizhuang Xili
    Chaoyang District
    Beijing
    CHN

    https://www.xzenithbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    342

Stocks News & Analysis

stocks

Cheap ASX share may have more room to run

Shares are cheap despite rebounding share price, yet risks remain.
stocks

ASX listed media giant drives strong earnings growth

Digital growth drives earnings beat for media share.
stocks

ASX real estate platform outperforms yet questions remain

Valuation remains a key concern despite strong August reporting.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,424.1013.30-0.14%
CAC 408,722.377.440.09%
DAX 4026,402.3782.920.32%
Dow JONES (US)54,036.93151.830.28%
FTSE 10010,876.5624.53-0.23%
HKSE25,937.49269.461.05%
NASDAQ26,690.62342.261.30%
Nikkei 22566,970.221,363.512.08%
NZX 50 Index13,888.2464.110.46%
S&P 5007,757.6447.680.62%
S&P/ASX 2009,232.6017.00-0.18%
SSE Composite Index3,966.5926.560.67%

Market Movers